Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?

Frontiers in Immunology(2020)10.3389/fimmu.2020.02021Source: DataRank Database

Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here? is a research paper published in Frontiers in Immunology (2020). On theSindex it has a DataRank of 0. It has been cited 103 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access103 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.79)OA: goldTopics (43)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Christine Couch ORCID,Davis Borucki ORCID,Amer Toutonji,Mohammed Alshareef ORCID,Stephen Tomlinson ORCID

Live enrichment

PubMed:33013859 OpenAlex:https://openalex.org/W3085355901

National Institutes of Health

Grant: 2T32GM008716-21

TRAINING PROGRAM FOR MEDICAL SCIENTISTS

National Institutes of Health

Grant: 3UL1TR001450-06S1

South Carolina Clinical & Translational Research Institute (SCTR)

National Institutes of Health

Grant: 1IK6BX005235-01

BLR&D Research Career Scientist Award Application for Dr. Stephen Tomlinson

National Institutes of Health

Grant: 2TL1TR001451-06

NRSA Training Core

National Institutes of Health

Grant: 1T32AI132164-01

Program in Immunology Research and Entrepreneurship (PIRE)

FWCI

2.79

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.02021/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.02021/pdf

publisherhttps://www.frontiersin.org/article/10.3389/fimmu.2020.02021/full

journalhttps://doi.org/10.3389/fimmu.2020.02021

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33013859

Fields of Study

Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsComplement system in diseases03 medical and health sciences0302 clinical medicine

MeSH Terms

Brain Injuries, TraumaticAnimalsAnti-Inflammatory AgentsCentral Nervous SystemCentral Nervous System DiseasesClinical Trials as TopicHumansNeuroprotective Agents

Keywords

NeuroprotectionNeuroinflammationNeuroscienceMedicineClinical trialContext (archaeology)DiseaseComplement systemNeurodegenerationImmune systemPharmacologyImmunologyBiologyPathologyCentral Nervous Systemclinical trialsamyotrophic lateral sclerosisClinical Trials as Topictraumatic brain injuryAnti-Inflammatory AgentsRC581-607multiple sclerosisstrokeNeuroprotective AgentsCentral Nervous System Diseasescomplement inhibitionBrain Injuries, TraumaticAnimalsHumansImmunologic diseases. Allergy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being